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Abstract
Prostate cancer is the most common form of cancer found in American males. Breaking technological advances in prostate
cancer treatment continue to develop to help fight this disease, one such is proton beam therapy. Proton beam therapy
is theorized to spare even more healthy tissue than photon radiotherapy because it delivers a majority of its radiation
during the Bragg peak. Since this technology is substantially costlier than any other form of radiation therapy, physicians
are assessing its effectiveness and determining if it is worth the cost. Currently, there is no significant difference seen in
patient quality of life between recipients of proton or photon therapy. This can possibly because of secondary neutrons
that are generated when protons exit the nozzle. Pencil beam scanning, a recent advancement in proton therapy delivery,
is theorized to make protons have much better treatment outcomes than photons and would eliminate the issue of
secondary neutrons. More studies need to be conducted to determine if pencil beam scanning ensure better quality of
life over photon therapy.
Introduction
Carcinoma of the prostate, more commonly known as prostate
cancer, is a malignant tumor that develops on the prostate –a
male organ that wraps around the urethra. Prostate cancer can
occur in many different forms, such as carcinoid, small-cell tumors, and ductal carcinoma, however, these types are extremely
rare and little is known about which treatment most effectively
eliminates them. The vast majority of cases are adenocarcinoma,
a tumor that originates in the gland cells. Prostatic adenocarcinoma is observed in over 95 percent of patients (National Cancer
Institute 2014) and affects 15 percent of men predominantly
above the age of 66, making it the most common cancer among
American males (SEER 2014). Fortunately, prostate cancer tends
to grow extremely slowly, and early treatment can often yield
high survival rates. The most common treatment interventions
for prostate cancer include surgery or radiation therapy. Within
radiation therapy there are two methods, external beam radiation therapy (EBRT) and internal radiation therapy.The latter, also
referred to as brachytherapy, involves the placement of radioactive pellets within the prostate gland that release a highly concentrated dose of radiation to eliminate the cancerous growth.
External beam radiation therapy is employed by using a linear
accelerator to accelerate electrons close to the speed of light
and strike them against a metal plate. On impact, high-energy,
ionizing photons are produced, which travel towards the targeted
cancerous cells. The high amount of energy in the photons can
irreparably damage vital structures in the cell such as DNA, RNA,
or protein. Photons are able to directly harm the cancerous cells’
DNA by energizing its electrons and pulling them out of their
orbits. This produces free radicals, causing irreversible damage by
altering the chemical structure of the nucleotides. Ionizing radiation can also delete, fragment, and translocate the nucleotides.
Radiation can also indirectly harm DNA when photons collide
with a cell’s water molecules and energize its electrons. When
a water molecule’s excited electrons bounce out of their orbits
it produces a hydroxyl ion (OH-). The hydroxyl ion is then able
to extract a hydrogen atom from the deoxyribose part of the
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DNA, ruining the nucleotide’s chemical configuration. Direct or
indirect radiation damage to a cancerous cell’s DNA is usually
lethal. This is because the uncontrollable growth of the prostate
cancer involves the mutation of the tumor suppressor gene TP53
(Wang et al. 1997). The protein that TP53 codes for is not only
responsible for regulating the cell cycle, it is also responsible
initiating DNA repair. As a result, cancerous cells are ineffective
at repairing radiated DNA, and the cell’s ability to proliferate is
practically destroyed. Damaging 1000 nucleotides in DNA only
takes one cobalt grey equivalent –the unit measure of radiation
used during treatment.
Although external beam is an effective form of treatment, it also
delivers radiation to surrounding healthy tissue. This is because
before the advent of image guided treatment, physicians had to
target the entire prostate to ensure that the entire tumor was
radiated. Additionally, since the dose of radiation is gradually reduced as the beam passes through the patient, tissue directly in
front of the tumor must be radiated to the prescribed dose. This
leaves a track of radiation damage as the photons enter the body
until it reaches the tumor. Furthermore, photons are massless
particles and are not stopped or slowed down when they impact
body tissue. This causes healthy tissue behind the tumor to receive radiation when photons travel past the tumor. Radiation to
nearby healthy tissue often causes gastrointestinal and genitourinary toxicity, which can impair the patient’s quality of life.
Advances in radiotherapy have greatly reduced these problems.
The advent of three-dimensional conformal radiotherapy (3DCRT) helps radiation oncologists treat prostate cancer more effectively.This sophisticated computer program creates a three-dimensional map to conform the radiation beam to the shape of
the cancer and its surrounding normal tissues. Concentrating the
beam more accurately to the cancerous area reduces the exposure of normal tissue to radiation, further reducing side effects
after treatment. More recent advances in high precision targeting have led to intensity-modulated radiotherapy (IMRT), where
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there is an even more effective manipulation of the radiation
beam.The beam in IMRT is divided into multiple ‘beamlets’, aimed
at the target from different directions. The ‘beamlets’’ shape and
intensity are adjusted to avoid radiating nearby healthy tissue. By
taking advantage of intensity-modulated ‘beamlets’, IMRT is able
to deliver higher doses of radiation to the prostate. This arguably
ensures greater eradication of cancerous cells while sparing even
more healthy tissue than 3D-CRT. Additional advances include
image-guided radiotherapy, which provides more accuracy to the
targeted area in the event that patients or the organs inside them
move during treatment.
Despite all the improvements in radiotherapy healthy tissue behind the tumor is still getting bombarded with radiation. Proton
therapy is able to stop this. Proton therapy involves the therapeutic use of protons to radiate the DNA of cancerous cells.
Protons are positively charged heavy particles, approximately
1800 times the mass of an electron. Therefore, protons need a
particle accelerator to strip hydrogen atoms of their electrons,
accelerate them to nearly the speed of light, and shoot them into
tumors. Particle accelerators, either cyclotrons or synchrotrons,
require an enormous amount of space, which makes the cost
of a particle accelerator exceed 100 million dollars (National
Association for Proton Therapy 2010). Upon entering the body,
protons slow down due to their heavy weight and their attraction to the electrons in the body’s cells. Consequently, physicians
must program the particle accelerators to provide the protons
with enough energy to reach the cancerous cells. After traveling
the specified distance protons stop abruptly, depositing most
of their energy at the targeted cells, sparing harmful radiation
to the healthy cells behind the tumor. This biologic phenomenon, of depositing high dose and energy of the beam within the
tumor while having minimal energy deposited beyond the tumor
is known as the Bragg Peak Effect. During radiation treatment,
physicians modify the Bragg peak and extend its distance to cover
the entire depth of the tumor, ensuring that the entire tumor
is radiated. Extending the distance of the Bragg Peak is accomplished by treating the tumor to different energies, which sends
multiple sprays of protons to different depths of the tumor. This
manipulation of the proton beam is called the Spread-Out Bragg
Peak. Additionally, protons do not deposit much radiation when
they enter the body. Taking advantage of the Bragg Peak Effect
and the low entrance dose, proton therapy should theoretically
achieve less exposure of radiation to normal tissue. This is believed to lead to higher prescribed doses, reduced complications
of therapy, and greater efficacy in eradication of the tumor than
any other form of radiotherapy.

Methods
Literature for this article was obtained using the Touro College
Online library, in particular PubMed.

Figure 1

The graph compares the Bragg peaks of IMRT vs. Proton beam therapy.
Protons, unlike photons, are clearly seen to delivery most of the radiation at
the targeted cell.
(Mohan et al. 2013)

Discussion
Over the past decade, intensity-modulated radiotherapy has become the standard form of radiation treatment for prostate cancer, accounting for more than 80% of all radiotherapy (Nguyen
2011). Although IMRT is the most common method of radiation
treatment, new forms of treatment are still emerging, most notably proton beam therapy. Proton therapy is currently being
implemented at various cancer centers across America because
of the excitement over the radiological advantages protons seem
to offer. Even though there is a lot of enthusiasm over PBT, no
factual evidence to prove protons are better than photons has
been found. The lack of evidence in conjunction with the enormous cost of delivering the treatment is compelling physicians
to determine if protons are more beneficial. To date there has
been no clinical study that establishes that protons have a major
advantage in cancer cure rates. This is because it is difficult to
conduct cure rate trials, since such differences take many years to
manifest.Therefore, the initial studies on proton therapy focus on
treatment related toxicity and quality of life (Pearson et al. 2007).
The organs most frequently affected by radiation toxicity after
treatments are the bladder and rectum.

Dosimetric Analysis
A dosimetric analysis is the estimated measurement of ionizing
radiation from the dose that is absorbed by nearby organs and
is projected before treatment is delivered. This analysis helps
physicians determine if there will be toxicity to nearby healthy
tissue, which can downgrade the patient’s quality of life. A study
comparing the dosimetry of intensity-modulated radiotherapy
and proton therapy was conducted to discover if protons spare
more healthy tissue than photons on the bladder and rectum.Ten
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patients were planned with both three dimensional conformal
proton therapy and intensity-modulated radiotherapy. The prescribed dose for both treatments was 79.2 cobalt gray-equivalent
(CGE) to the prostate gland. The study concluded that protons
reduce the area of nearby healthy tissue that inadvertently receives low to medium, but not high doses of radiation. In contrast,
intensity-modulated radiotherapy spreads more low and medium doses of radiation over a larger area of the pelvis (Table 1)
(Trofimov et al. 2007). IMRT likely ‘bathes’ the pelvis with low to
medium doses of radiation because it uses multiple ‘beamlets’ to
target the tumor from different directions. As a result, there are
more entry points into the patient’s body as radiation is shot
from the linear accelerator to the tumor.
More significant results were reported by a study from the
University of Florida.The study also used 10 patients to compare
proton beam therapy treatment with intensity-modulated radiotherapy, but with a prescribed dose of 78 CGE (Table 1) (Vargas et
al. 2008). The difference in results between the study by Trofimov
et al, in comparison to Vargas et al, can most probably be attributed to the difference in beam margins and arrangement. To be
certain the cancerous growth was completely radiated, Trofimov
et al, added a 10 mm margin around the clinical target volume,
Vargas et al, only added 5 mm by 8 mm. By minimizing the margins, Vargas was able to better conform the beam to the tumor.
When IMRT was delivered both studies used 7 beams, 52° apart
from each other. However, for proton therapy, only Vargas et al
optimized the beams. Beam angle optimization means physicians
determine the ‘beamlet’ angles and intensities, so that the beams
strike the tumor while sparing as much normal tissue as possible.
Two steps are taken when determining the correct beam angle
Table 1

Author
Trofimov

Vargas

Chera

Dosimetric

Value

Bladder

A clinical investigation conducted by Chera et al, did not use
beam angle optimization, but used the same prescribed dose and
similar margins to Vargas et al (Table 1). Chera et al, concluded
that the, “use of PBT significantly reduced the dose to normal
tissues in the pelvis while maintaining adequate target coverage
compared with IMRT” (Chera et al. 2009). Although the absolute difference between the two treatments was greater in the
study by Chera et al,Vargas et al, managed to spare slightly more
healthy tissue. One can conclude that beam margins play a more
important role in limiting radiation from healthy tissue than beam
arrangement.
In a recent study about the dosimetric impact on anatomical
movements, Zhang et al, noted that the proton beam is affected
by compensators that shape the beam at the end of the nozzle.
As a result, protons experience more scatter than photons and
minimizing the margins is extremely crucial. Although a dosimetric analysis was not the main focus of their study, Zhang et al
reported that, “The proton therapy plan was better at sparing the
rectum at doses of less than 50 Gy. However, above 50 Gy, IMRT
was better at sparing the rectum” (Zhang et al. 2007). Clearly, all
studies confirm that proton therapy reduces the amount of low
to medium radiation unintentionally delivered to nearby healthy
tissue. Yet, IMRT can sometimes yield better conformity to the
target area in cases where high doses are delivered.

Rectum

Absolute Difference
Bladder / Rectum

30% CGE

44.5%(IMRT) / 32.8%(PBT)

65.3%(IMRT) / 43.8%(PBT)

11.7% / 21.5%

70% CGE

11.4%(IMRT) / 17.3%(PBT)

9.7%(IMRT) / 10.3%(PBT)

5.9% / 0.6%

30% CGE

42.8%(IMRT) / 27.7%(PBT)

55.4%(IMRT) / 20.7%(PBT)

15.1% / 34.7%

78% CGE

—

5%(IMRT) / 2.9%(PBT)

- / 2.1%

30% CGE

73.1%(IMRT) / 29.3%(PBT)

71.8%(IMRT) / 22.5%(PBT)

43.8% / 49.3%

70% CGE

9.7%(IMRT) / 9.8%(PBT)

11.5%(IMRT) / 7.9%(PBT)

0.1% / 3.6%

Dosimetric Analysis Comparing IMRT Versus PBT (Pearlstein et. al 2013)
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and intensity. “First, the physicians through their experience and
intuition decide the arrangement of the beams. Secondly, based
on the orientation of the beams and the shape of the cancer,
computer software optimizes the beam intensities.” (Bertsimas
et al. 2013).

Proton Beam Therapy

Toxicity and Quality of Life
Radiation poisoning of healthy tissue caused by protons can irritate the bladder, cause frequent urination, rectal bleeding, and
sexual dysfunction. The question is, does toxicity to surrounding
normal tissue result from the combined low and medium dose
areas or the high dose area? A clinical investigation compared the
rate of second cancers between IMRT and 3D-CRT. The study
found that IMRT almost doubles the amount of second malignancies from 1% to 1.75%. This is because IMRT increases the
amount of low dose radiation absorbed by surrounding healthy
tissue (Hall et al. 2003). With this information it should follow
that proton therapy, which substantially reduces low to medium
unintentionally absorbed radiation should have significantly lower
toxicity rates than IMRT.
A study was launched to discover if proton therapy causes less
toxicity to nearby organs than intensity-modulated and three-dimensional conformal radiotherapy. There were 95 proton therapy patients, 153 IMRT patients, and 123 3D-CRT patients. Every
patient’s bowel and urinary functions were assessed 3, 12, and 24
months after treatment. The Expanded Prostate Cancer Index
Composite (EPIC) was used to grade patients that received IMRT.
Patients that received PBT or 3D-CRT were evaluated with the
Prostate Cancer Symptom Indices, a similar scale to EPIC. In
both tests scoring lower signifies lower quality of life. At three
months following treatment, patients who received 3D-CRT or
IMRT scored lower on the indices. They reported symptoms of
urinary irritation, obstruction, incontinence, and a decrease in
bowel quality of life. Proton therapy patients only reported minimal bowel and urinary morbidity. At 12 months all groups were
equal on the indices when they reported decreased bowel quality
of life. Only proton therapy patients reported a slight decrease
in quality of urinary functions, such as irritation and obstruction,
in comparison to the other groups. By 24 months all groups
reported minor but clinically meaningful decrements in bowel
and urinary functions quality of life. Proton therapy had a slight
advantage for toxicities after 3 months and IMRT and 3D-CRT
only had a slight advantage for urinary toxicities at 12 months. All
groups had the same level of toxicity 24 months later. However,
there are problems with this study. Firstly, each group received a
slightly different dose to the prostate: 75.6 to 79.2 CGE for the
IMRT patients, and 74.0 to 82.0 CGE for PBT patients. Different
doses of radiation could have caused the different patterns of
toxicity reported by the patients. Also, treatment was delivered
according to each center’s preferred practice and planning target
volume margins were not explicitly mandated (Gray et al. 2013).
Another study on whether PBT can control the incidence of rectal toxicity only comprised of patients receiving the same dose,
74 CGE. Patients were followed up with after treatment to collect data on the toxicities at 1 month and once every 3 months

for the first two years and once every 6 months thereafter. The
rectal toxicities observed included anal pain at defecation and
rectal bleeding. The bladder toxicities were urinary frequency,
painful urination, and urinary retention.The patients were graded
with the Common Toxicity Criteria 4.0, a scale created by the
National Cancer Institute Grade 1 toxicity usually means minor
toxicity. Grade 2 means symptoms requiring medications and
grade 3 means symptoms requiring minor corrective surgery.The
results revealed that PBT can achieve a low occurrence of grade
2 rectal toxicities and no major late toxicity was seen. (Nihei et al.
2011).The study by Nihei et al, takes care of some of the issues of
the trial by Gray et al, that were mentioned earlier. Each patient
had the same dose of radiation. In both studies a low amount of
rectal toxicity is seen early on.
More significant results were found by a study conducted by
Mendenhall et al. The authors used image-guided proton therapy
to target the cancerous tissue. They discovered low amounts of
grade 2 genitourinary and gastrointestinal toxicities (Mendenhall
et al. 2012). These toxicity results do appear more favorable than
results commonly reported with IMRT. There was a high incidence of grade 1 and 2, and some patients experienced grade 3
toxicity. (Valeriani et al. 2014). Even more surprising was the fact
that Valeriani et al, used image-guided IMRT and the prescribed
dose was much lower, 68 CGE. The image guided radiation and
the low amount of radiation should have curtailed the amount of
toxicity that was reported.
Only one study reported overall worse gastrointestinal toxicity rates for protons than photons. The study used data from
Surveillance, Epidemiology, and End Results (SEER), a Medicare
linked database. Sheets et al, analyzed patient reported outcomes
based on billing claims for diagnoses and procedures from sixteen cancer registries. There were 684 patients treated with
proton therapy and 6666 with IMRT. The authors observed that,
“proton therapy–treated patients were more likely to receive a
diagnosis of gastrointestinal morbidity and undergo gastrointestinal procedures” (Sheets et al. 2012). However, this investigation
did not report information on the prescribed dose and target
margins. If the dose and margins differed between the two groups
it could have caused a difference in toxicity rates. Another issue
with this study is that Sheets et al, used claims for colonoscopy
to measure gastrointestinal toxicity rates. This would be an imprecise surrogate for any population. This is the same population
that might also be more concerned about colonoscopy screening,
and therefore would receive more gastrointestinal procedures.
This study should not be used to relay any important morbidity
information to inquiring patients. The few studies on quality of
life have only shown modest advantages associated with proton
therapy in comparison with other forms of radiotherapy.
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Problems with Scatter Beam Proton Therapy
Theoretically, protons should be the superior form of radiation
treatment because of the Bragg Peak Effect. However, this phenomenon also makes the protons extremely sensitive to uncertainties during treatment. If a physician is unsure how deeply
situated the tumor is, protons will not destroy the cancerous
cells if it is not given even energy to reach that area. In contrast,
photons continue to deposit a substantial amount of radiation
as they transverse the entire body. As a result, physicians end
up programming the Spread-Out Bragg Peak to extend deeper
into the body, irradiating nearby healthy tissue. Additionally, the
Spread-Out Bragg Peak requires multiple shots of protons to be
passed through the body to completely radiate the entire depth
of the tumor. This causes the tissue in the front of the prostate
to be exposed to many doses of radiation. Additional concerns
have recently been raised that organ toxicity can also be a result
of secondary neutrons. Secondary neutrons are created when
protons collide with the collimator –a metal piece that shapes
the beam. The collimator is made out of brass and when struck
by protons it sends off secondary neutrons. Low secondary neutron radiation can cause patients receiving treatment to develop
a high chance for contracting second malignancies (Brenner et al.
2008). These neutrons could be stopping PBT from having better
toxicity results. Although there are simple fixes to reduce the
amount of neutrons, such as using a material with a low mass
number, these techniques do not substantially curtail the amount
of neutrons (Gould 2009).

Pencil Beam Scanning
Recently, a newer method of delivery has been added to proton therapy. The older method, Scatter beam uses thick beams
of passively scattered protons. The beams are shaped through
slits in metal plates that form a relatively large beam as it exits
the particle accelerator. The latest improvement to proton beam
therapy is pencil beam scanning. Also known as spot scanning, this
method is more accurate version of proton therapy. Pencil beam
employs an extremely narrow beam that is brushed from side to
side, ‘painting’ the dose on the tumor spot by spot. Because no
apertures are needed, the protons do not collide with any metal
and secondary neutrons are not produced with the collimator.
The beam targets each spot on the tumor with a specific dose
of radiation. Pencil beam scanning can even adjust the Spread-out
Bragg Peak for every individual cancerous cell. “Scattered beam
and pencil beam can be compared to a painter spraying with a
spray can versus an airbrush. Instead of needing a stencil to master the shape, the proton beam is made ultra fine to define the
contours and landscape of a tumor” (MD Anderson 2009). With
pencil beam protons are turned into an intensity-modulated type
of treatment.This is projected to give protons more conformation
to the cancer and its surrounding healthy tissues. Recently, a small
number of cancer centers that deliver proton therapy introduced
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this new technology (Weisenbaugh 2014).To date, it is premature
to determine if pencil beam is the most optimal method to use
in the fight against prostate cancer. Only one study concluded
that there is no toxicity or quality of life differences between
passively scattered and pencil beam. The clinical investigation was
comprised of 226 men who received passively scattered proton
therapy and 65 men who received pencil beam proton therapy.
Both groups reported similar gastrointestinal toxicity results,
grade 2, throughout the 24-month trial. Genitourinary toxicity
was also grade 2 and occurred mostly in the first 12 months
following treatment. Yet, the authors acknowledged that, “Future
comparative analyses between spot-scanning and passively scattered are warranted in a larger cohort” (Pugh et al. 2013).

Conclusion
Proton beam therapy can cure prostatic adenocarcinoma as efficiently as IMRT. If proton therapy would not be extremely expensive this therapy would be less controversial. Protons would have
been regarded as another type of treatment used to eradicate
cancerous cells. However, because proton therapy is considerably more expensive it draws criticism to the fact that it only
has a meager benefit over IMRT. PBT is slightly more effective
in curtailing the amount of low to medium dose of radiation to
the nearby organs. However, this only translates into a modest
advantage in early toxicity over intensity-modulated radiotherapy. Currently, there is no clinical evidence that proves scatter
beam proton therapy is a significantly better form of treatment
than IMRT. However, since there are limited centers that deliver
proton therapy and relatively few patients that received it, more
studies need to be conducted to solidify this claim. Although
scatter beam might not be so advantageous in comparison to
intensity-modulated radiotherapy, pencil beam proton therapy is
theorized to turn protons into the ultimate form of treatment.
More clinical trials need to be conducted to find out if pencil
beam technology gives proton therapy the edge in the battle
against prostate cancer.
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